References
- Aalbers R, Vogelmeier C, Kuna P. Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respir Med. 2016;111:1–7. doi:https://doi.org/10.1016/j.rmed.2015.11.002.
- Global Initiative for Asthma (GINA). 2020. Global Strategy for asthma management and prevention. Updated 2020. Available from: https://ginasthma.org/gina-reports/. Accessed: 30 September 2020.
- Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy. 2014;4(2):75–85. doi:https://doi.org/10.5415/apallergy.2014.4.2.75.
- Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting beta2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respir Med. 2018;141:111–120. doi:https://doi.org/10.1016/j.rmed.2018.06.009.
- Balki A, Balamurugan S, Bardapurkar S, Dalal S, Singh A, Singh BP, Vaidya A, Gogtay JA. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial. Pulm Pharmacol Ther. 2018;48:28–36. doi:https://doi.org/10.1016/j.pupt.2017.09.001.
- Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;(5):CD005535. doi:https://doi.org/10.1002/14651858.CD005535.pub2.
- Nakamura Y, Tamaoki J, Nagase H, Yamaguchi M, Horiguchi T, Hozawa S, Ichinose M, Iwanaga T, Kondo R, Nagata M, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020;69(4):519–548. doi:https://doi.org/10.1016/j.alit.2020.08.001.
- Kim DK, Park YB, Oh YM, Jung KS, Yoo JH, Yoo KH, Kim KH, Steering and Scientific Committee of Asthma Study Group and Guideline Control Committee in The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD). Korean Asthma Guideline 2014: Summary of Major Updates to the Korean Asthma Guideline 2014. Tuberc Respir Dis (Seoul). 2016;79(3):111–120. doi:https://doi.org/10.4046/trd.2016.79.3.111.
- Asthma Workgroup, Chinese Thoracic Society, Chinese Societ of General Practitioners. Chinese guideline for the prevention and management of bronchial asthma (Primary Health Care Version). J Thorac Dis. 2013;5:667–677.
- Respiratory Diseases Branch of the Chinese Medical Association Bronchial asthma therapeutic guidelines. Definition, diagnosis, treatment, education and management of bronchial asthma. Chin J Tuberc Respir Dis. 2003;26:132–138. (Chinese).
- Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, Prasad KT, Yenge LB, Singh N, Behera D, et al. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India. 2015;32(Suppl 1):S3–S42. doi:https://doi.org/10.4103/0970-2113.154517.
- Dal Negro RW, Bonadiman L, Turco P. Fluticasone furoate/Vilanterol 92/22μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 µg b.i.d.: a 12-month comparison of outcomes in mild-to-moderate asthma. Multidiscip Respir Med. 2018;13(1):18. doi:https://doi.org/10.1186/s40248-018-0131-x.
- Averell CM, Stanford RH, Laliberte F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–110. doi:https://doi.org/10.1080/02770903.2019.1663429.
- Buhl R, Heaney LG, Loefroth E, Larbig M, Kostikas K, Conti V, Cao H. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med. 2020;162:105859. doi:https://doi.org/10.1016/j.rmed.2019.105859.
- Schatz M, Meckley LM, Kim M, Stockwell BT, Castro M. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy. J Allergy Clin Immunol Pract. 2014;2(5):570–574. doi:https://doi.org/10.1016/j.jaip.2014.05.002.
- Shimizu Y, Shiobara T, Arai R, Chibana K, Takemasa A. Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study). J Thorac Dis. 2020;12(5):1877–1883. doi:https://doi.org/10.21037/jtd-19-3913.
- Canadian Agency for Drugs and Technologies in Health (CADTH). Long-acting beta(2)-agonist and inhaled corticosteroid combination therapy for adult persistent asthma: systematic review of clinical outcomes and economic evaluation. CADTH Technol Overv. 2010;1:e0120.
- Rogala B, Majak P, Gluck J, Dębowski T. Asthma control in adult patients treated with a combination of inhaled corticosteroids and long‑acting β2‑agonists: a prospective observational study. Pol Arch Intern Med. 2017;127(2):100–106. doi:https://doi.org/10.20452/pamw.3899.
- Price D, David-Wang A, Cho SH, Ho JC, Jeong JW, Liam CK, Lin J, Muttalif AR, Perng DW, Tan TL, et al. Asthma in Asia: Physician perspectives on control, inhaler use and patient communications. J Asthma. 2016;53(7):761–769. doi:https://doi.org/10.3109/02770903.2016.1141951.
- Global Asthma Network. The global asthma report 2018. Auckland, New Zealand: Global Asthma Network, 2018.
- Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–220. doi:https://doi.org/10.1016/j.anai.2013.06.008.
- Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, Chowdhry VK, Favro D, Lanfear DE, Pladevall M. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–1191 e2. doi:https://doi.org/10.1016/j.jaci.2011.09.011.
- van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8(10):987–999. doi:https://doi.org/10.1016/S2213-2600(20)30178-8.
- Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D’Andrea P. IRIDIUM trial investigators. Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:https://doi.org/10.1016/S2213-2600(20)30190-9.
- Chapman KR, van Zyl-Smit RN, Maspero JF, Kerstjens HAM, Gon Y, Hosoe M, Tanase AM, Pethe A, Shu X, D’Andrea P. Once-daily mometasone/indacaterol fixed-dose combination versus twice-daily fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies. BMJ Open Resp Res. 2021;e000819.
- Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying ‘well-constrolled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med. 2006;100(4):616–621. doi:https://doi.org/10.1016/j.rmed.2005.08.012.
- Juniper EF, O′Byrne PM, Guyatt Gh, Ferrie Pj, King Dr. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:https://doi.org/10.1034/j.1399-3003.1999.14d29.x.
- Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, Fu JJ, Wang L, Gibson PG, Wang G. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol. 2013;131(3):695–703. doi:https://doi.org/10.1016/j.jaci.2012.08.023.
- Barnes PJ, Casale TB, Dahl R, Pavord ID, Wechsler ME. The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use. Allergy. 2014;69(9):1119–1140. doi:https://doi.org/10.1111/all.12415.
- Vogelmeier C, Naya I, Ekelund J. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study. Clin Drug Investig. 2012;32(7):439–449. doi:https://doi.org/10.2165/11598840-000000000-00000.
- Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23–27. doi:https://doi.org/10.1034/j.1399-3003.1999.14a06.x.
- Bousquet J, Boulet L-P, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer Å. Å. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101(12):2437–2446. doi:https://doi.org/10.1016/j.rmed.2007.07.014.
- Svedsater H, Stynes G, Wex J, Frith L, Leather D, Castelnuovo E, Detry M, Berry S. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma-mixed treatment comparisons of clinical efficacy. Asthma Res Pract. 2016;2:4. doi:https://doi.org/10.1186/s40733-015-0016-0.
- Inman M D, Watson R M, Rerecich TACY, Gauvreau G M, Lutsky B N, Stryszak PAUL, O’Byrne P M. dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med. 2001;164(4):569–574. doi:https://doi.org/10.1164/ajrccm.164.4.2007063.
- Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56(7):748–757. doi:https://doi.org/10.1080/02770903.2018.1490751.